Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

The Effects of PDE Inhibitors on Multiple Sclerosis: a Review of in vitro and in vivo Models

Author(s): Alexandra Ainatzoglou, Eleni Stamoula, Ioannis Dardalas, Spyridon Siafis and Georgios Papazisis*

Volume 27, Issue 20, 2021

Published on: 03 March, 2021

Page: [2387 - 2397] Pages: 11

DOI: 10.2174/1381612827666210303142356

Price: $65

Abstract

Background: Multiple sclerosis (MS) is a chronic inflammatory and immune-mediated disease, whose current therapeutic means are mostly effective in the relapsing-remitting form of MS, where inflammation is still prominent, but fall short of preventing long term impairment. However, apart from inflammationmediated demyelination, autoimmune mechanisms play a major role in MS pathophysiology, constituting a promising pharmacological target. Phosphodiesterase (PDE) inhibitors have been approved for clinical use in psoriasis and have undergone trials suggesting their neuroprotective effects, rendering them eligible as an option for accessory MS therapy.

Objective: In this review, we discuss the potential role of PDE inhibitors as a complementary MS therapy.

Methods: We conducted a literature search through which we screened and comparatively assessed papers on the effects of PDE inhibitor use, both in vitro and in animal models of MS, taking into account a number of inclusion and exclusion criteria.

Results: In vitro studies indicated that PDE inhibitors promote remyelination and axonal sustenance, while curbing inflammatory cell infiltration, hindering oligodendrocyte and neuronal loss and suppressing cytokine production. In vivo studies underlined that these agents alleviate symptoms and reduce disease scores in MS animal models.

Conclusion: PDE inhibitors proved to be effective in addressing various aspects of MS pathogenesis both in vitro and in vivo models. Given the latest clinical trials proving that the PDE4 inhibitor Ibudilast exerts neuroprotective effects in patients with progressive MS, research on this field should be intensified and selective PDE4 inhibitors with enhanced safety features should be seriously considered as prospective complementary MS therapy.

Keywords: MS, PDE inhibitors, Rolipram, EAE, in vivo, in vitro, immunomodulation.

« Previous Next »
[1]
Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372(9648): 1502-17.
[http://dx.doi.org/10.1016/S0140-6736(08)61620-7] [PMID: 18970977]
[2]
Tsang BKT, Macdonell R. Multiple sclerosis- diagnosis, management and prognosis. Aust Fam Physician 2011; 40(12): 948-55.
[PMID: 22146321]
[3]
Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple Sclerosis: Mechanisms and Immunotherapy Neuron 2018; 742-68. Available from: https://pubmed.ncbi.nlm.nih.gov/29470968/
[4]
Multiple sclerosis - NHS. Available from: https://www.nhs.uk/conditions/multiple-sclerosis/
[5]
Multiple Sclerosis Treatment & Management: Approach Considerations, Emergency Department Management Treatment of Acute Relapses. Available from: https://emedicine.medscape.com/article/1146199-treatment
[6]
Aktas O, Kieseier B, Hartung HP. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci 2010; 33(3): 140-52.
[http://dx.doi.org/10.1016/j.tins.2009.12.002] [PMID: 20045200]
[7]
Dutta R, Trapp BD. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol Prog Neurobiol. 2011; pp. 1-12. Available from: https://pubmed.ncbi.nlm.nih.gov/20946934/
[8]
Juanatey A, Blanco-García L, Téllez N. efficacy and safety in multiple sclerosis. Rev Neurol Revista de Neurologia 2018; 66: 423-33. Available from: https://pubmed.ncbi.nlm.nih.gov/29897610/
[9]
Rommer PS, Milo R, Han MH, et al. Immunological aspects of approved MS therapeutics Front Immunol 2019. Available from: https://pubmed.ncbi.nlm.nih.gov/31354720/
[10]
Multiple Sclerosis Information Page National Institute of Neurological Disorders and Stroke Available from: https://www.ninds.nih.gov/disorders/all-disorders/multiple-sclerosis-information-page
[11]
Fox RJ, Coffey CS, Conwit R, et al. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.N Engl J Med. Massachusetts Medical Society 2018; 379: pp. 846-55.
[12]
Kumar N, Goldminz AM, Kim N, Gottlieb AB. Phosphodiesterase 4-targeted treatments for autoimmune diseases BMC Med BMC Med 2013. Available from: https://pubmed.ncbi.nlm.nih.gov/23557064/
[13]
Kang EJ, Kavanaugh A. Psoriatic arthritis: Latest treatments and their place in therapy. Ther Adv Chronic Dis Ther Adv Chronic Dis. 2015; pp. 194-203. Available from: https://pubmed.ncbi.nlm.nih.gov/26137209/
[14]
Grigoriadis N, Grigoriadis S, Polyzoidou E, Milonas I, Karussis D. Neuroinflammation in multiple sclerosis: Evidence for autoimmune dysregulation, not simple autoimmune reaction. Clin Neurol Neurosurg. 2006; pp. 241-4. Available from: https://pubmed.ncbi.nlm.nih.gov/16388896/
[15]
Weiner HL. The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease? Ann Neurol Ann Neurol. 2009; pp. 239-48. Available from: https://pubmed.ncbi.nlm.nih.gov/19334069/
[16]
Aktas O, Waiczies S, Smorodchenko A, et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 2003; 197: 725-33. Available from: https://pubmed.ncbi.nlm.nih.gov/12629065/
[17]
Youssef S, Stüve O, Patarroyo JO, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78-84. Available from: https://pubmed.ncbi.nlm.nih.gov/12422218/
[18]
Pieretti S, Dominici L, Di Giannuario A, Cesari N, Dal Piaz V. Local anti-inflammatory effect and behavioral studies on new PDE4 inhibitors. Life Sci 2006; 79: 791-800. Available from: https://pubmed.ncbi.nlm.nih.gov/16546218/
[http://dx.doi.org/10.1016/j.lfs.2006.02.026]
[19]
Vijayakrishnan L, Rudra S, Eapen MS, Dastidar S, Ray A. Small-molecule inhibitors of PDE-IV and -VII in the treatment of respiratory diseases and chronic inflammation. Expert Opin Investig Drugs Expert Opin Investig Drugs. 2007; pp. 1585-99. Available from: https://pubmed.ncbi.nlm.nih.gov/17922623/
[20]
Spina D. PDE4 inhibitors: Current status. Br J Pharmacol Br J Pharmacol. 2008; pp. 308-15. Available from: https://pubmed.ncbi.nlm.nih.gov/18660825/
[21]
Christensen SB, Guider A, Forster CJ, et al. 1998.https://pubmed.ncbi.nlm.nih.gov/9526558/
[22]
Wachtel H, Schneider HH. Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors. Neuropharmacology 1986; 25(10): 1119-26.
[http://dx.doi.org/10.1016/0028-3908(86)90159-0] [PMID: 2946976]
[23]
O’Donnell JM, Zhang HT. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci 2004; 25(3): 158-63.
[http://dx.doi.org/10.1016/j.tips.2004.01.003] [PMID: 15019272]
[24]
Bardin P, Kanniess F, Gauvreau G, Bredenbröker D, Rabe KF. Roflumilast for asthma: Efficacy findings in mechanism of action studies. Pulm Pharmacol Ther 2015; 35(Suppl): S4-S10.
[http://dx.doi.org/10.1016/j.pupt.2015.08.006] [PMID: 26296794]
[25]
Parikh N. Phosphodiesterase 4 (PDE4) inhibitors in the treatment of COPD: promising drug candidates and future directions. Curr Med Chem 2016; 23(2): 129-41.
[http://dx.doi.org/10.2174/0929867323666151117121334] [PMID: 26572614]
[26]
Haber SL, Hamilton S, Bank M, Leong SY, Pierce E. Apremilast: a novel drug for treatment of psoriasis and psoriatic arthritis. Ann Pharmacother 2016; 50(4): 282-90.
[http://dx.doi.org/10.1177/1060028015627467] [PMID: 26783350]
[27]
Ruiz-Pérez D, Benito J, Polo G, et al. The effects of the toll-like receptor 4 antagonist, ibudilast, on sevoflurane's minimum alveolar concentration and the delayed remifentanil-induced increase in the minimum alveolar concentration in rats. Anesth Analg 2016; 122(5): 1370-6.
[http://dx.doi.org/10.1213/ANE.0000000000001171] [PMID: 26859874]
[28]
Sanftner LM, Gibbons JA, Gross MI, Suzuki BM, Gaeta FCA, Johnson KW. Cross-species comparisons of the pharmacokinetics of ibudilast 2009.https://www.tandfonline.com/doi/abs/10.3109/00498250903254340
[29]
Barkhof F, Hulst HE, Drulović J, Uitdehaag BMJ, Matsuda K, Landin R. Ibudilast in relapsing-remitting multiple sclerosis: A neuroprotectant? 2010. Available from: https://pubmed.ncbi.nlm.nih.gov/20200338/
[http://dx.doi.org/10.1212/WNL.0b013e3181d7d651]
[30]
Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: Lessons learned and future perspectives. Lancet Neurol. Lancet Publishing Group 2015; pp. 208-23. Available from: https://pubmed.ncbi.nlm.nih.gov/25772899/
[31]
Bermel RA, Fedler JK, Kaiser P, et al. Optical coherence tomography outcomes from SPRINT-MS, a multicenter, randomized, double-blind trial of ibudilast in progressive multiple sclerosis.Mult Scler J. SAGE Publications Ltd 2020.
[32]
Sun X, Liu Y, Liu B, Xiao Z, Zhang L. Rolipram promotes remyelination possibly via MEK-ERK signal pathway in cuprizone-induced demyelination mouse. Exp Neurol 2012; 237(2): 304-11.
[http://dx.doi.org/10.1016/j.expneurol.2012.07.011] [PMID: 22836144]
[33]
Paintlia AS, Paintlia MK, Singh I, Skoff RB, Singh AK. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis 2009; 57(2): 182-93. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18720408/?tool=EBI
[http://dx.doi.org/10.1002/glia.20745]
[34]
Jung S, Zielasek J, Köllner G, Donhauser T, Toyka K, Hartung HP. Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J Neuroimmunol 1996; 68(1-2): 1-11.
[http://dx.doi.org/10.1016/0165-5728(96)00051-3] [PMID: 8784254]
[35]
Syed YA, Baer A, Hofer MP, et al. Inhibition of phosphodiesterase-4 promotes oligodendrocyte precursor cell differentiation and enhances CNS remyelination.EMBO Mol Med 2013; 5: 1918-34.Available from.
[http://dx.doi.org/10.1002/emmm.201303123]
[36]
Duarte-Silva E, Araújo SM da R, Oliveira WH. Sildenafil ameliorates EAE by decreasing apoptosis in the spinal cord of C57BL/6 mice.J Neuroimmunol 2018; 321: 125-37. Available from:
[http://dx.doi.org/10.1016/j.jneuroim.2018.06.002]
[37]
Pifarré P, Gutierrez-Mecinas M, Prado J, et al. Phosphodiesterase 5 inhibition at disease onset prevents experimental autoimmune encephalomyelitis progression through immunoregulatory and neuroprotective actions. Exp Neurol 2014; 251: 58-71.
[http://dx.doi.org/10.1016/j.expneurol.2013.10.021] [PMID: 24211383]
[38]
Fujimoto T, Sakoda S, Fujimura H, Yanagihara T. Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J Neuroimmunol 1999; 95: 35-42. Available from: https://pubmed.ncbi.nlm.nih.gov/10229113/
[39]
Dinter H, Tse J, Halks-Miller M, et al. The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents. J Neuroimmunol 2000; 108: 136-46. Available from: https://pubmed.ncbi.nlm.nih.gov/10900347/
[40]
Medina-Rodríguez EM, Bribián A, Boyd A, et al. Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. Sci Rep 2017; 7: 43545.
[http://dx.doi.org/10.1038/srep43545] [PMID: 28256546]
[41]
Redondo M, Brea J, Perez DI, et al. Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds. J Med Chem 2012; 55(7): 3274-84.
[http://dx.doi.org/10.1021/jm201720d] [PMID: 22385507]
[42]
González-García C, Bravo B, Ballester A, et al. Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis 2013. Available from: https://pubmed.ncbi.nlm.nih.gov/23869659/
[http://dx.doi.org/10.1111/bph.12308]
[43]
Jung S, Donhauser T, Toyka KV, Hartung HP. Propentofylline and iloprost suppress the production of TNF-α by macrophages but fail to ameliorate experimental autoimmune encephalomyelitis in Lewis rats. J Autoimmun 1997; 10(6): 519-29.
[http://dx.doi.org/10.1006/jaut.1997.0159] [PMID: 9451591]
[44]
Muñoz-Esquivel J, Göttle P, Aguirre-Cruz L, et al. Sildenafil Inhibits Myelin Expression and Myelination of Oligodendroglial Precursor Cells. ASN Neuro 2019; 11: 1759091419832444.
[http://dx.doi.org/10.1177/1759091419832444] [PMID: 30849920]
[45]
Bielekova B, Lincoln A, McFarland H, Martin R. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J Immunol 2000; 164(2): 1117-24.
[http://dx.doi.org/10.4049/jimmunol.164.2.1117] [PMID: 10623864]
[46]
Sloka S, Metz LM, Hader W, Starreveld Y, Yong VW. Reduction of microglial activity in a model of multiple sclerosis by dipyridamole. J Neuroinflammation 2013; 10: 89. Available from: https://pmc/articles/PMC3724584/?report=abstract
[47]
Yoshikawa M, Suzumura A, Ito A, Tamaru T, Takayanagi T. Effect of phosphodiesterase inhibitors on nitric oxide production by glial cells. Tohoku J Exp Med 2002; 196: 167-77.
[http://dx.doi.org/10.1620/tjem.196.167]
[48]
Zhang B, Yang L, Konishi Y, Maeda N, Sakanaka M, Tanaka J. Suppressive effects of phosphodiesterase type IV inhibitors on rat cultured microglial cells: comparison with other types of cAMP-elevating agents. Neuropharmacology 2002; 42(2): 262-9.
[http://dx.doi.org/10.1016/S0028-3908(01)00174-5] [PMID: 11804623]
[49]
Sunke R, Bankala R, Thirupataiah B, et al. InCl3 mediated heteroarylation of indoles and their derivatization via CH activation strategy: Discovery of 2-(1H-indol-3-yl)-quinoxaline derivatives as a new class of PDE4B selective inhibitors for arthritis and/or multiple sclerosis. Eur J Med Chem 2019; 174: 198-215.
[http://dx.doi.org/10.1016/j.ejmech.2019.04.020] [PMID: 31035240]
[50]
Suzumura A, Sawada M. Effects of vesnarinone on cytokine production and activation of murine microglia. Life Sci 1999; 64(14): 1197-203.
[http://dx.doi.org/10.1016/S0024-3205(99)00051-X] [PMID: 10210262]
[51]
Sommer N, Löschmann PA, Northoff GH, et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis 1995. Available from: https://pubmed.ncbi.nlm.nih.gov/7585041/
[http://dx.doi.org/10.1038/nm0395-244]
[52]
Maida E, Kristoferitsch W. 1981. Available from: https://link.springer.com/article/10.1007/BF00313327
[53]
Schillace RV, Carr DW. The role of protein kinase A and A-kinase anchoring proteins in modulating T-cell activation: Progress and future directions. Crit Rev Immunol Crit Rev Immunol. 2006; pp. 113-31. Available from: https://pubmed.ncbi.nlm.nih.gov/16700649/
[54]
Domeniconi M, Filbin MT. Overcoming inhibitors in myelin to promote axonal regeneration. J Neurol Sci. J Neurol Sci. 2005; pp. 43-7. Available from: https://pubmed.ncbi.nlm.nih.gov/15949495/
[55]
Yang Y, Wang H, Zhang J, et al. Cyclin dependent kinase 5 is required for the normal development of oligodendrocytes and myelin formation. 2013. Available from: https://pubmed.ncbi.nlm.nih.gov/23583582/
[http://dx.doi.org/10.1016/j.ydbio.2013.03.023]
[56]
Luo FC, Burke K, Kantor C, Miller RH, Yang Y. Cyclin-dependent kinase 5 mediates adult OPC maturation and myelin repair through modulation of Akt and GsK-3β signaling. J Neurosci Society for Neuroscience 2014; 34: 10415-29. Available from: https://pmc/articles/PMC4115145/?report=abstract
[57]
Gupta A, Tsai L-H. Cyclin-Dependent Kinase 5 and Neuronal Migration in the Neocortex. Neurosignals 2003; 12: 173-9. Available from: https://www.karger.com/Article/FullText/74618
[http://dx.doi.org/10.1159/000074618]
[58]
Chang A, Tourtellotte WW, Rudick R, Trapp BD. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 2002; 346: 165-73. Available from: https://pubmed.ncbi.nlm.nih.gov/11796850/
[59]
Fyffe-Maricich SL, Karlo JC, Landreth GE, Miller RH. The ERK2 mitogen-activated protein kinase regulates the timing of oligodendrocyte differentiation. J Neurosci 2011; 31: 843-50. Available from: https://www.jneurosci.org/content/31/3/843
[60]
Newbern JM, Li X, Shoemaker SE, et al. Specific Functions for ERK/MAPK Signaling during PNS Development. Neuron 2011; 69: 91-105. Available from: https://pubmed.ncbi.nlm.nih.gov/21220101/
[61]
Whitaker CM, Beaumont E, Wells MJ, Magnuson DSK, Hetman M, Onifer SM. Rolipram attenuates acute oligodendrocyte death in the adult rat ventrolateral funiculus following contusive cervical spinal cord injury. Neurosci Lett NIH Public Access 2008; 438: 200-4.
[http://dx.doi.org/10.1016/j.neulet.2008.03.087]
[62]
Sánchez AJ, Puerta C, Ballester S, González P, Arriaga A, García-Merino A. Rolipram impairs NF-κB activity and MMP-9 expression in experimental autoimmune encephalomyelitis. J Neuroimmunol 2005; 168: 13-20. Available from: http://www.jni-journal.com/article/S0165572805003796/fulltext
[63]
Hartung HP, Kieseier BC. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol. 2000; pp. 140-7. Available from: https://pubmed.ncbi.nlm.nih.gov/10854648/
[64]
Kieseier BC, Kiefer R, Clements JM, et al. Matrix metalloproteinase-9 and-7 are regulated in experimental autoimmune encephalomyelitis. Brain 1998; 121: 159-66. Available from: https://www.researchgate.net/publication/51338653
[http://dx.doi.org/10.1093/brain/121.1.159]
[65]
Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991; 87: 949-54. Available from: https://pmc/articles/PMC329886/?report=abstract
[66]
Zhang L, Xie H, Cui L. Activation of astrocytes and expression of inflammatory cytokines in rats with experimental autoimmune encephalomyelitis. Exp Ther Med 2018; 16: 4401-6. Available from: https://pubmed.ncbi.nlm.nih.gov/30546391/
[http://dx.doi.org/10.3892/etm.2018.6798]
[67]
Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988; 23: 339-46. Available from: https://pubmed.ncbi.nlm.nih.gov/3132891/
[http://dx.doi.org/10.1002/ana.410230405]
[68]
Powell MB, Mitchell D, Lederman J, et al. Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int Immunol 1990; 2: 539-44. Available from: https://pubmed.ncbi.nlm.nih.gov/1707660/
[http://dx.doi.org/10.1093/intimm/2.6.539]
[69]
Il Yup Chung, Norris JG, Benveniste EN. Differential tumor necrosis factor α expression by astrocytes from experimental allergic encephalomyelitis-susceptible and -resistant rat strains. J Exp Med 1991; 173: 801-11. Available from: https://pmc/articles/PMC2190814/?report=abstract
[70]
Ruddle NH, Bergman CM, McGrath KM, et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990; 172: 1193-200. Available from: https://pubmed.ncbi.nlm.nih.gov/2212948/
[71]
Kinzel S, Weber MSB. B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence CNS Drugs 2016; 1137-48. Available from: https://pubmed.ncbi.nlm.nih.gov/27844213/
[72]
Lehmann Horn K, Kronsbein HC, Weber MS. Targeting B cells in the treatment of multiple sclerosis: Recent advances and remaining challenges. Ther Adv Neurol Disord Ther Adv Neurol Disord 2013; pp. 161-173. Available from: https://pubmed.ncbi.nlm.nih.gov/23634189/
[73]
Harp CT, Ireland S, Davis LS, et al. Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4+ T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur J Immunol 2010; 40: 2942-56. Available from: https://pubmed.ncbi.nlm.nih.gov/20812237/
[74]
Grewal IS, Flavell RA. The Role of CD40 Ligand in Costimulation and T-Cell Activation. Immunol Rev 1996; 153: 85-106. Available from: https://pubmed.ncbi.nlm.nih.gov/9010720/
[75]
Martin S, Agarwal R, Murugaiyan G, Saha B. CD40 Expression Levels Modulate Regulatory T Cells in Leishmania donovani Infection. J Immunol 2010; 185: 551-9. Available from: http://www.jimmunol.org/content/185/1/551
[76]
Genç K, Dona DL, Reder AT. Increased CD80+ B cells in active multiple sclerosis and reversal by interferon β-1b therapy. J Clin Invest 1997; 99: 2664-71. Available from: https://pubmed.ncbi.nlm.nih.gov/9169496/
[77]
Bielekova B, Richert N, Howard T, et al. Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood-brain barrier disruption in multiple sclerosis. Mult Scler 2009; 15: 1206-14. Available from: https://pubmed.ncbi.nlm.nih.gov/19776093/
[http://dx.doi.org/10.1177/1352458509345903]
[78]
Briones-Buixassa L, Milà R, Ma Aragonès J, Bufill E, Olaya B, Arrufat FX. Stress and multiple sclerosis: A systematic review considering potential moderating and mediating factors and methods of assessing stress Heal Psychol Open 2015. Available from: https://pubmed.ncbi.nlm.nih.gov/28070374/
[79]
Faissner S, Mishra M, Kaushik DK, et al. Systematic screening of generic drugs for progressive multiple sclerosis identifies clomipramine as a promising therapeutic. Nat Commun 2017; 8: 1-15. Available from: www.nature.com/naturecommunications
[http://dx.doi.org/10.1038/s41467-017-02119-6]

Rights & Permissions Print Cite
Article Metrics
60
1
World Chronic Fatigue Syndrome Awareness Day
© 2024 Bentham Science Publishers | Privacy Policy